Alkermes PLC (ALKS) Director Paul J. Mitchell Sells 1,500 Shares

Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $50.64, for a total value of $75,960.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Alkermes PLC (NASDAQ ALKS) traded up 0.86% during mid-day trading on Wednesday, reaching $51.87. The company’s stock had a trading volume of 346,573 shares. The company’s 50-day moving average price is $50.95 and its 200 day moving average price is $55.96. Alkermes PLC has a 52 week low of $41.93 and a 52 week high of $63.40. The firm’s market capitalization is $7.97 billion.

Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The company had revenue of $218.80 million during the quarter, compared to analysts’ expectations of $216.54 million. During the same quarter last year, the company posted ($0.01) EPS. The firm’s revenue was up 12.1% compared to the same quarter last year. On average, equities analysts forecast that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Alkermes PLC (ALKS) Director Paul J. Mitchell Sells 1,500 Shares” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://sportsperspectives.com/2017/10/04/alkermes-plc-alks-director-paul-j-mitchell-sells-1500-shares.html.

A number of hedge funds have recently modified their holdings of the business. Greenwood Capital Associates LLC boosted its position in Alkermes PLC by 1.1% in the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after buying an additional 41 shares during the period. PNC Financial Services Group Inc. boosted its position in Alkermes PLC by 0.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,104 shares of the company’s stock valued at $415,000 after buying an additional 42 shares during the period. World Asset Management Inc boosted its position in Alkermes PLC by 1.9% in the 2nd quarter. World Asset Management Inc now owns 6,939 shares of the company’s stock valued at $402,000 after buying an additional 128 shares during the period. Capstone Asset Management Co. boosted its position in Alkermes PLC by 2.6% in the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock valued at $392,000 after buying an additional 170 shares during the period. Finally, M&T Bank Corp boosted its position in Alkermes PLC by 2.9% in the 2nd quarter. M&T Bank Corp now owns 7,135 shares of the company’s stock valued at $413,000 after buying an additional 200 shares during the period. 99.07% of the stock is owned by institutional investors.

A number of research analysts have recently commented on ALKS shares. ValuEngine raised Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Jefferies Group LLC set a $69.00 target price on Alkermes PLC and gave the company a “buy” rating in a research note on Friday, August 25th. BidaskClub cut Alkermes PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. J P Morgan Chase & Co set a $78.00 target price on Alkermes PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. Finally, Credit Suisse Group reiterated a “buy” rating and issued a $70.00 price target on shares of Alkermes PLC in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $64.13.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply